GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (NAS:BIIB) » Definitions » Shiller PE Ratio

BIIB (Biogen) Shiller PE Ratio : 6.44 (As of Jul. 14, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Biogen Shiller PE Ratio?

As of today (2025-07-14), Biogen's current share price is $133.525. Biogen's E10 for the quarter that ended in Mar. 2025 was $20.73. Biogen's Shiller PE Ratio for today is 6.44.

The historical rank and industry rank for Biogen's Shiller PE Ratio or its related term are showing as below:

BIIB' s Shiller PE Ratio Range Over the Past 10 Years
Min: 5.56   Med: 18.72   Max: 69.67
Current: 6.44

During the past years, Biogen's highest Shiller PE Ratio was 69.67. The lowest was 5.56. And the median was 18.72.

BIIB's Shiller PE Ratio is ranked better than
95.25% of 526 companies
in the Drug Manufacturers industry
Industry Median: 27.24 vs BIIB: 6.44

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2025 was $1.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $20.73 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biogen Shiller PE Ratio Historical Data

The historical data trend for Biogen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Shiller PE Ratio Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.16 13.53 13.69 12.51 7.37

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.23 10.94 9.20 7.37 6.60

Competitive Comparison of Biogen's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.


;
;

Biogen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=133.525/20.73
=6.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.64/134.9266*134.9266
=1.640

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 3.930 100.684 5.267
201509 4.150 100.392 5.578
201512 3.770 99.792 5.097
201603 4.430 100.470 5.949
201606 4.790 101.688 6.356
201609 4.710 101.861 6.239
201612 2.990 101.863 3.961
201703 3.460 102.862 4.539
201706 4.070 103.349 5.314
201709 5.790 104.136 7.502
201712 -1.410 104.011 -1.829
201803 5.540 105.290 7.099
201806 4.180 106.317 5.305
201809 7.150 106.507 9.058
201812 4.730 105.998 6.021
201903 7.150 107.251 8.995
201906 7.850 108.070 9.801
201909 8.390 108.329 10.450
201912 8.080 108.420 10.055
202003 8.080 108.902 10.011
202006 9.590 108.767 11.896
202009 4.460 109.815 5.480
202012 2.320 109.897 2.848
202103 2.690 111.754 3.248
202106 2.990 114.631 3.519
202109 2.220 115.734 2.588
202112 2.500 117.630 2.868
202203 2.060 121.301 2.291
202206 7.240 125.017 7.814
202209 7.840 125.227 8.447
202212 3.790 125.222 4.084
202303 2.670 127.348 2.829
202306 4.070 128.729 4.266
202309 -0.470 129.860 -0.488
202312 1.710 129.419 1.783
202403 2.700 131.776 2.765
202406 4.000 132.554 4.072
202409 2.660 133.029 2.698
202412 1.830 133.157 1.854
202503 1.640 134.927 1.640

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biogen  (NAS:BIIB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Biogen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Biogen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Executives
Priya Singhal officer: Head of Development C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114
Caroline Dorsa director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Jane Grogan officer: Head of Research BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Susan Langer director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Ginger Gregory officer: EVP, Human Resources C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Adam Keeney officer: Head of Corporate Development BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Christopher Viehbacher director, officer: President and CEO C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Susan H Alexander officer: EVP, General Counsel C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Nicole Murphy officer: Head of Pharm Ops and Tech BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Rachid Izzar officer: Head of Alzheimer's Disease BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Alfred Sandrock officer: Grp SVP, Chief Medical Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Chirfi Guindo officer: EVP Glob. Mkt Acc & Cust Innov C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142